New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 21, 2015
16:33 EDTAAPLApple shares drop 8% to $120.56 following Q3 report
Subscribe for More Information
16:33 EDTAAPLApple reports Q3 iPhone units 47.53M vs. 61.17M last quarter
Subscribe for More Information
16:31 EDTAAPLApple reports Q3 gross margin 39.7% vs. 39.4% last year
International sales accounted for 64% of the quarter’s revenue.
16:30 EDTAAPLApple sees Q4 revenue $49B-$51B, consensus $51.05B
Sees Q4 gross margin 38.5%-39.5%.
16:30 EDTAAPLApple reports Q3 EPS $1.85, consensus $1.81
Reports Q3 revenue $49.6B, consensus $49.31B.
16:01 EDTAAPLOptions Update; July 21, 2015
iPath S&P 500 VIX Short-Term Futures down 13c to 16.20. Option volume leaders: AAPL BAC FB BAC MSFT NFLX AMD IBM CHK
15:56 EDTAAPLApple July weekly 131 straddle priced for 5.2% movement into Q3
15:02 EDTAAPLNotable companies reporting after market close
Subscribe for More Information
14:14 EDTAAPLEarnings Watch: Apple flat since last report with iPhone, Watch results in focus
Subscribe for More Information
14:02 EDTGOOGYouTube pulls Streamus app, Variety reports
Subscribe for More Information
13:43 EDTAAPLApple services restored after nearly 4-hour outage, CNBC reports
Subscribe for More Information
13:33 EDTGOOGGoogle acquires Pixate, terms not disclosed
Subscribe for More Information
13:21 EDTAAPLApple July weekly 131 straddle priced for 4.7% movement into Q3
12:59 EDTGOOGEarnings Watch: Tax questions linger into Yahoo Q2 report
Subscribe for More Information
12:47 EDTSNY, REGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:39 EDTAAPLApple experiencing issues with App Store, iTunes Store, CNBC reports
Subscribe for More Information
10:05 EDTAAPLApple technical notes ahead of results
The stock has been trading in a range since February of this year that is bound by a low at $120 and a high at $133. There have been three touches at the range high since then and two tests at the low suggesting the bias is for a breakout. If the news is strongly bullish, notably around China sales and guidance, a breakout above $133 and the brief life high at $134.54 would be highly probable. Based on the height of the range the upside potential would be to $147 to $150. Without overhead resistance, price could continue to drift beyond that objective depending on the strength of the news. If the news is a bearish surprise, which very few expect, the low of the range would likely be tested for a third time. A breakdown below $120 would have the same range expectations as on the upside, with a downside target potential to $107 to $105 implied from the range height. Such a move would break the 10-month moving average at $122.16 which has been a good proxy for the uptrend that began off lows in August 2013. The last time this average was broken was during the downturn in price in late 2012 which then ended in August 2013.
10:01 EDTGMCROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:35 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB IBM TSLA BAC PVA NFLX
09:06 EDTGOOGADT Corp. announces partnership with Nest Labs
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use